Inventor
LANG WIEGAND
DE12 patents
⚠️ This page may combine multiple inventors who share the name “LANG WIEGAND”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CSL BEHRING GMBH
5 patentsUS7863009B2Jan 4, 2011
Mutants of the factor VII-activating protease and detection methods using specific antibodies
CSL BEHRING GMBH0 citations49
US7442514B2Oct 28, 2008
Mutants of the factor VII-activating protease and detection methods using specific antibodies
CSL BEHRING GMBH0 citations49
US7803569B2Sep 28, 2010
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
CSL BEHRING GMBH0 citations47
US7863006B2Jan 4, 2011
Antibodies for specifically detecting pathogenic prions of human origin, and detection methods carried out using these antibodies
CSL BEHRING GMBH0 citations46
US7829095B2Nov 9, 2010
Inhibitory monoclonal antibody against blood clotting factor VII-activating protease
CSL BEHRING GMBH0 citations45
WEIMER THOMAS
3 patentsUS8575104B2Nov 5, 2013
Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
WEIMER THOMAS18 citations89
US8765915B2Jul 1, 2014
Modified coagulation factor VIIa with extended half-life
WEIMER THOMAS8 citations79
US9290561B2Mar 22, 2016
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
WEIMER THOMAS1 citations49
AVENTIS BEHRING GMBH
3 patentsUS6831167B2Dec 14, 2004
Mutants of the factor VII-activating protease and detection methods using specific antibodies
AVENTIS BEHRING GMBH9 citations71
US7153679B2Dec 26, 2006
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
AVENTIS BEHRING GMBH9 citations69
US6479245B1Nov 12, 2002
Monoclonal antibody which is specific for activated coagulation factor VII, and its use
AVENTIS BEHRING GMBH2 citations62